If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Emgality Summary of Product Characteristics (SmPC)
Emgality®▼ (galcanezumab): New packaging
Changes to the galcanezumab pre-filled pen carton and packaging materials occurred in August 2020. Slight changes to the carton size, carton closure and the location of the carton graphics were implemented.
tamper evident seal was removed and replaced by a glue dot.
orientation of the information contained on the label and
Instructions for Use was slightly changed. It might not be noticeable
to the user.1
lock ring position on the pre-filled pen should be in the locked
position when a new carton is first opened and the pre-filled pen is
first removed from the carton. There are multiple checks in the
manufacturing process to ensure the lock ring is in the locked
position during assembly and labeling.1
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:September 30, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org